After obtaining an accession of more than 86% in its proposal to restructure debt for more than US$42 million and extend maturities until 2029, Rizobacter received a signal from the financial market. The FIX qualifier raised the long-term note of the company from CC (arg) to B (arg), with a stable perspective. The rise also reached all existing negotiable obligations (ON) — Series VIII, IX, X and XI — and the short-term issuer rating, which went…
After obtaining an accession of more than 86% in its proposal to restructure debt for more than US$42 million and extend maturities until 2029, Rizobacter received a signal from the financial market. The FIX qualifier raised the long-term note of the company from CC (arg) to B (arg), with a stable perspective. The rise also reached all existing negotiable obligations (ON) — Series VIII, IX, X and XI — and the short-term issuer rating, which went…